The power of our people
Diversity & Inclusion is an integral part of Boehringer Ingelheim's identity.
Search
What do you know about transboundary animal diseases
Transboundary animal diseases (TADs) are highly transmissible diseases of livestock that can impact veterinary public health preparedness.
Transboundary animal diseases and veterinary preparedness
What are transboundary animal diseases (TADs)? Bluetongue virus, foot-and-mouth disease and avian influenza are pathogens belonging to this group.
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
The generalized pustular psoriasis (GPP) Forum 2023
An executive summary of the activities and key takeaways from the GPP Forum 2023
Fight against COVID-19 pandemic
Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
Award: Boehringer Ingelheim is Global Top Employer 2022
Global Top Employer 2022
2019 performance
Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
Who are we?
Started in 1885 by Albert Boehringer, this independent family-owned company has grown into a top contributor in Human Pharma and Animal Health.
2021 PRRS Research Award winners announced
The 2021 European PRRS Research Award winners announced
Generalized pustular psoriasis: The Impact Beyond The Skin
An article on how the symptoms of generalized pustular psoriasis (GPP) are more than just physical, affecting both mental and emotional health
Generalized pustular psoriasis at EADV 2021
Dr. Emmanuelle Clerisme-Beaty (former Associate Head of Medicine - Inflammation, Boehringer Ingelheim) reflects on developments for GPP at the EADV congress, 2021
Advancing health equity for rural doctors in Mexico
Our virtual sales team helps doctors stay informed through digital education about the latest treatments, regardless of their location
Blue internal teat sealant now in dairy mastitis portfolio
Boehringer Ingelheim adds blue internal teat sealant to its dairy mastitis portfolio
Jean-Michel Boers Appointed to PhRMA Board of Directors
Jean-Michel Boers Appointed to PhRMA Board of Directors
AMR_Action_Fund
Boehringer Ingelheim joins AMR Action Fund to support antibiotic R&D
Partnering pet therapeutics
Learn more about our research focus and our most recent partnerships regarding pet therapeutics.
Boehringer upgrade in Access to Medicine Health Ranking
Boehringer’s focus on Health Equity drives significant upgrade in Access to Medicine Index Ranking
Our goal of transforming the treatment of neuroendocrine carcinomas
Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).
Global language learning platform for our people
One global learning platform for languages, countless opportunities to grow your career
Brand of the Year Frontline pet parasiticides
FRONTLINE® Wins Brand of the Year Award for the Third Time in a row
China pioneers biosecurity report against ASF
Boehringer Ingelheim compiles data from 1,000 swine farms into the first market report on biosecurity. Document sheds light on livestock management and contributes to the fight against African swine fever.
George Okafo
My career challenge at Boehringer Ingelheim by George Okafo. Read it now!
PREVEXXION® RN: Marek’s disease vaccine available in EU UK
Boehringer Ingelheim is pleased to announce the launch of the next generation of Marek’s disease vaccines is now available in the EU.
digital_leader_award_2020
Boehringer Ingelheim wins first place in the "STRATEGY" category of the Digital Leader Award